Merck Stock (NYSE:MRK) Upgraded To Buy

HSBC analysts have recently boosted their recommendation on Merck shares (NYSE: MRK) to a Buy rating, moving up from a previous Hold. This upgrade is accompanied by a maintained price target of $130. The analysts base this decision on Merck’s strategic approach towards imminent patent expirations and its robust position in oncology.

Merck's strategy focuses on extending the earnings potential of its oncology portfolio. This is especially significant given the company’s expertise in oncology and a strong clinical pipeline. As clinical successes become evident, analysts expect increased recognition of Merck's pipeline value.

In 2025, Merck faces several notable opportunities, the stabilisation of Gardasil’s revenue in China could be a significant contributor, the progress on subcutaneous formulations of Keytruda could provide additional market advantages, and the introduction of Winrevir presents further growth prospects

HSBC's analysis of Merck highlights a balanced view of imminent opportunities and risks. The upgrade to a Buy rating reflects confidence in Merck's strategic direction and its capacity to manage upcoming challenges effectively. While risks remain, particularly related to its product pipeline and market conditions, Merck’s efforts in oncology and strategic innovations signify positive long-term prospects.